Search by drug, manufacturer, or indication

Displaying 901 - 910 of 1165

Rosiver (ivermectin)

Status:

Concluded without agreement

Manufacturer:

Galderma Canada Inc.

Indication:

Rosacea

Last updated May 23, 2018

Elelyso (taliglucerase alfa)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Gaucher disease

Last updated May 17, 2018

Lynparza (olaparib)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

Last updated May 15, 2018

Vectibix (panitumumab)

Status:

Negotiations were not pursued

Manufacturer:

Amgen Canada Inc.

Indication:

Left Sided Metastatic Colorectal Cancer

Last updated May 10, 2018

Kyleena (levonorgestrel)

Status:

Concluded with an LOI

Manufacturer:

Bayer Inc.

Indication:

Conception Control

Last updated April 20, 2018

VPRIV (velaglucerase)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Gaucher disease

Last updated April 16, 2018

Zinbryta (daclizumab beta)

Status:

Negotiations were not pursued

Manufacturer:

Biogen Canada Inc.

Indication:

Multiple Sclerosis, Relapsing

Last updated March 29, 2018

Zykadia (ceritinib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated March 20, 2018

Glatect (glatiramer acetate)

Status:

Concluded with an LOI

Manufacturer:

Pendopharm, a division of Pharmascience Inc.

Indication:

Multiple Sclerosis, Relapsing-Remitting

Last updated March 1, 2018

Botox (onabotulinumtoxin a)

Status:

Concluded with an LOI

Manufacturer:

Allergan Inc.

Indication:

Multiple Indications

Last updated February 28, 2018